{'fraction_non_alphanumeric': 0.035058430717863104, 'fraction_numerical': 0.021702838063439065, 'mean_word_length': 5.666666666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Review of the ESPRIT Study: Aspirin plus Dipyridamole versus Aspirin Alone for Prevention of Vascular Events after a Noncardioembolic, Mild-to-Moderate Ischemic Stroke or Transient Ischemic Attack

Practice Pearl This trial demonstrated the efficacy of combination therapy with dosages of aspirin (30–325 mg/day) plus dipyridamole (200 mg twice daily) in the prevention of vascular events after a noncardioembolic, mild-to-moderate ischemic stroke or transient ischemic attack, and showed a clear benefit of the aspirin/dipyridamole combination regimen over an aspirin-alone (30–325 mg/day) regimen.